Corcept trades GR-II antagonist royalties for non-dilutive cash from Pharmakon
00:20 EDT 9 Aug 2012 | SCRIP
Corcept Therapeutics has sold a total of $45 million worth of royalties for the recently launched Cushing's syndrome drug Korlym (mifepristone 300mg tablets) and any of its next-generation drugs in the same GR-II antagonist class to Pharmakon Advisor..
Original Article: Corcept trades GR-II antagonist royalties for non-dilutive cash from Pharmakon
More From BioPortfolio on "Corcept trades GR-II antagonist royalties for non-dilutive cash from Pharmakon"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
